Don't miss an issue! Renew/subscribe for FREE today.

BioHorizons Offers Dentists the Most Comprehensive Grafting Portfolio Worldwide

Posted on Tuesday, October 14, 2014

BIRMINGHAM, Ala., -- Oct. 10, 2014 -- BioHorizons, an oral reconstructive device company, today announced the launch of MinerOss® X, a family of xenograft products for dental implant site development procedures. The MinerOss® X family includes cancellous or cortical particulate, a moldable collagen block, and a cancellous particulate pre-loaded into a delivery syringe to assist with optimal placement. It is designed for extraction sockets, grafting for implant placement, ridge augmentation, and sinus augmentation.

"MinerOss® X represents a significant addition to our innovative tissue regeneration product portfolio. MinerOss® X is a xenograft alternative for predictable bone regeneration and complements our highly successful line of MinerOss® allografts. With this product line, BioHorizons offers dentists the most complete portfolio of regenerative hard and soft tissue grafting products," said Steve Boggan, President and CEO of BioHorizons.

MinerOss® X particulates range in size from 250 to 1000 microns providing excellent handling characteristics for a wide variety of regeneration procedures. MinerOss® X particulate is available in 0.25g, 0.5g, 1.0g and 2.0g easily accessible vials with a convenient screw-top lid. MinerOss® X syringe is available in 0.25cc, 0.5cc and 1.0cc sizes for added convenience during surgery. MinerOss® X collagen is also available in three sizes to support large and small grafting cases.

About BioHorizons

BioHorizons, Inc., a majority-owned subsidiary of Henry Schein, Inc. (NASDAQ: HSIC), is a leading dental implant and biologics company located in Birmingham, Alabama. The company has a broad product offering, including dental implants, surgical planning software and tissue regeneration solutions for the replacement of missing teeth. BioHorizons products are available in 85 markets around the world. For more information, visit

Recent Headlines

© 2024 BroadcastMed LLC | Privacy Policy